Surgical treatment of patient with combination of amiodaron-induced thyrotoxic and esophagesl cancer
Alexander S. Kuzmichev,
Konstantin V. Pavelets,
Alexey L. Akinchev,
Mikhail A. Protchenkov,
Vasiliy I. Lomakin,
Mikhail K. Pavelets,
Sergey A. Kalyuzhny,
E. V. Shepichev https://doi.org/10.14341/serg12695
Abstract
The article presents the successful experience of surgical treatment of a patient with a malignant tumor of the esophagus, which was detected in a patient with amiodarone-induced thyrotoxicosis. Thyroidectomy made it possible to quickly eliminate thyrotoxicosis and timely perform radical surgery for esophageal cancer.
About the Authors
Alexander S. Kuzmichev
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
MD, PhD, professor
St. Petersburg
Konstantin V. Pavelets
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
MD, PhD, professor
St. Petersburg
Alexey L. Akinchev
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
MD, PhD
St. Petersburg
Mikhail A. Protchenkov
Mariinsky City Hospital
Russian Federation
Russian Federation
MD, PhD
St. Petersburg
Vasiliy I. Lomakin
Mariinsky City Hospital
Russian Federation
Russian Federation
MD
St. Petersburg
Mikhail K. Pavelets
Mariinsky City Hospital
Russian Federation
Russian Federation
MD
St. Petersburg
Sergey A. Kalyuzhny
Mariinsky City Hospital
Russian Federation
Russian Federation
MD
St. Petersburg
E. V. Shepichev
Mariinsky City Hospital
Russian Federation
Russian Federation
MD
St. Petersburg
References
1. Serdyuk SYe, Bakalov SA, Soboleva VA, et al. Amiodar-associated thyroid dysfunction: developmental frequency, correction possibilities. Cardiology. 2004;44(10):32-37. (In Russ.).
2. Melnichenko GA, Sviridenko NYu, Molashenko NV, et al. Amyodarone-induced thyroid dysfunction (pathogenesis, diagnosis, treatment). Therapeutic archive. 2003;75(8):92-96. (In Russ.).
3. Mkrtumyan AM, Biryukova YV, Yegshatyan LV, et al. Amiodarone-Induced Thyrotoxicosis Type 1: Features of Patient Management. Effective farmacotherapy. 2019;15(25):8-12. (In Russ.). doi: https://doi.org/10.33978/2307-3586-2019-15-25-8-11
4. Lebedeva EA, Iablonskaia IA, Bulgakova SV. Amiodarone-induced thyrotoxicosis: state of the art. Clinical and experimental thyroidology. 2017;13(2):31-38. (In Russ.). doi: https://doi.org/10.14341/ket2017231-38
5. Tomisti L, Rossi G, Bartalena L, et al. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014;171(3):363-368. doi: https://doi.org/10.1530/EJE-14-0267
6. Jabrocka-Hybel A, Bednarczuk T, Bartalena L, et al. Amiodaron i tarczyca. Endokrynol Pol. 2015;66(2):176-196. doi: https://doi.org/10.5603/EP.2015.0025
7. Kotwal A, Clark J, Lyden M, et al. Thyroidectomy for Amiodarone-Induced Thyrotoxicosis: Mayo Clinic Experience. J Endocr Soc. 2018;2(11):1226-1235. doi: https://doi.org/10.1210/js.2018-00259
8. Minimum clinical recommendations of the European Society of Medical Oncology (ESMO). Ed by Tyulyandin SA, Nosov DA, Perevodchikova NI. Moscow: Publishing group RONC n.a. N.N. Blokhin RAMS; 2010. 436 p. (In Russ.).
9. Kavaykin D, Chichevatov D. Prevention of bronchopulmonary complications after intrapleural esophagoplasty with cancer of the esophagus. Vrach. 2012;10:78-80. (In Russ.).
Supplementary files
Review
For citations:
Kuzmichev A.S., Pavelets K.V., Akinchev A.L., Protchenkov M.A., Lomakin V.I., Pavelets M.K., Kalyuzhny S.A., Shepichev E.V. Surgical treatment of patient with combination of amiodaron-induced thyrotoxic and esophagesl cancer. Endocrine Surgery. 2020;14(4):26-29. (In Russ.) https://doi.org/10.14341/serg12695
Views:
708
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
